Literature DB >> 2568209

Population pharmacokinetic analysis of bisoprolol.

J Grevel1, P Thomas, B Whiting.   

Abstract

The technique of population pharmacokinetic analysis was employed to study the variability in the dose concentration relationship of bisoprolol during its clinical development. The influence of demographic factors on the variability of clearance was investigated in 3 different populations: group I, patients (including an elderly group) with essential hypertension receiving multiple oral doses of bisoprolol 10 or 20mg for 3 months; group II, patients with different degrees of renal impairment and healthy controls; and group III, patients with different types of hepatic impairment and healthy controls. Patients and controls in groups II and III received only a single oral dose of bisoprolol 10mg. The 3 data sets were analysed separately, using a non-linear mixed effects model (the NONMEM program). A 2-compartment pharmacokinetic model with first-order absorption described the data adequately. The typical values of volume of central compartment, volume of distribution at steady-state and the absorption rate constant for the 3 populations were: for group I, 68L, 235L, and 0.7h-1; for group II, 28L, 179L, and 0.3h-1; and for group III, 55L, 256L, and 0.4h-1, respectively. Plasma clearance was related to age in group I, to serum creatinine in group II and to aspartate transaminase activity in group III. The 68% confidence limits for clearance and elimination half-life were 8.2 to 21.5 L/h and 7.6 to 19.7h, respectively, for 50-year-old patients in group I. The analysis predicted that progressive increases in serum creatinine or aspartate transaminase activity will result in only a 50% reduction of clearance.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2568209     DOI: 10.2165/00003088-198917010-00005

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  13 in total

Review 1.  Bisoprolol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in hypertension and angina pectoris.

Authors:  S G Lancaster; E M Sorkin
Journal:  Drugs       Date:  1988-09       Impact factor: 9.546

2.  Estimation of population characteristics of pharmacokinetic parameters from routine clinical data.

Authors:  L B Sheiner; B Rosenberg; V V Marathe
Journal:  J Pharmacokinet Biopharm       Date:  1977-10

3.  Pharmacokinetic approach to drug dosing in the aged.

Authors:  W A Ritschel
Journal:  J Am Geriatr Soc       Date:  1976-08       Impact factor: 5.562

4.  Transection of the oesophagus for bleeding oesophageal varices.

Authors:  R N Pugh; I M Murray-Lyon; J L Dawson; M C Pietroni; R Williams
Journal:  Br J Surg       Date:  1973-08       Impact factor: 6.939

5.  Premarketing observational studies of population pharmacokinetics of new drugs.

Authors:  L B Sheiner; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  1985-11       Impact factor: 6.875

6.  Basic pharmacokinetics of bisoprolol, a new highly beta 1-selective adrenoceptor antagonist.

Authors:  G Leopold; J Pabst; W Ungethüm; K U Bühring
Journal:  J Clin Pharmacol       Date:  1986 Nov-Dec       Impact factor: 3.126

7.  Pharmacokinetics of bisoprolol during repeated oral administration to healthy volunteers and patients with kidney or liver disease.

Authors:  W Kirch; I Rose; H G Demers; G Leopold; J Pabst; E E Ohnhaus
Journal:  Clin Pharmacokinet       Date:  1987-08       Impact factor: 6.447

8.  Determination of the new beta-blocker bisoprolol and of metoprolol, atenolol and propranolol in plasma and urine by high-performance liquid chromatography.

Authors:  K U Bühring; A Garbe
Journal:  J Chromatogr       Date:  1986-10-31

9.  Pharmacokinetics and metabolism of bisoprolol-14C in three animal species and in humans.

Authors:  K U Bühring; H Sailer; H P Faro; G Leopold; J Pabst; A Garbe
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

10.  Pharmacodynamic models of various beta blockers: an explanation for the long duration of action of bopindolol.

Authors:  J Grevel
Journal:  J Cardiovasc Pharmacol       Date:  1986       Impact factor: 3.105

View more
  6 in total

1.  Evaluation of hypothesis testing for comparing two populations using NONMEM analysis.

Authors:  D B White; C A Walawander; D Y Liu; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1992-06

2.  Interaction between structural, statistical, and covariate models in population pharmacokinetic analysis.

Authors:  J R Wade; S L Beal; N C Sambol
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

3.  Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease.

Authors:  Valentina N Nikolic; Slobodan M Jankovic; Marina Deljanin-Ilic; Sanja S Stojanovic; Miroslav Lj Nikolic; Slavoljub Zivanovic; Dragana Stokanovic; Tatjana Jevtovic-Stoimenov; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2018-02       Impact factor: 2.441

4.  Population pharmacokinetics of bisoprolol in patients with chronic heart failure.

Authors:  Valentina N Nikolic; Tatjana Jevtovic-Stoimenov; Radmila Velickovic-Radovanović; Stevan Ilic; Marina Deljanin-Ilic; Dragan Marinkovic; Svetlana Apostolović; Dragana Stanojevic; Slavoljub Zivanovic; Nikola Stefanovic; Srdjan Pesic; Dejana Ruzic Zecevic; Jasmina R Milovanovic; Slobodan M Jankovic
Journal:  Eur J Clin Pharmacol       Date:  2012-10-24       Impact factor: 2.953

5.  Pharmacokinetic analysis of azelaic acid disodium salt. A proposed substrate for total parenteral nutrition.

Authors:  A Bertuzzi; A Gandolfi; S Salinari; G Mingrone; E Arcieri-Mastromattei; E Finotti; A V Greco
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

6.  In Silico comparison between metoprolol succinate and bisoprolol on 24-hour systolic blood pressures.

Authors:  Sven-Olof Jansson; Anders E Malm; Torbjörn Lundström
Journal:  Drugs R D       Date:  2014-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.